TC BioPharm (TCBP) said Monday it completed dosing for the first group B patient in the Achieve Phase 2B UK trial assessing TCB008 in acute myeloid leukemia.
The first group B patient received the dose in October, the company said, adding the person has received all four planned doses of TCB008 and is expected to get an additional fifth dose.
Meanwhile, enrollment of a second group B patient has also been started, the company said, adding group B recruitment is also continuing at sites in the UK.
"The therapy has been well-tolerated with no unexpected events or toxicities observed and promising efficacy results observed in some patients, with additional data being collected and analyzed," said TC BioPharm Chief Executive Bryan Kobel.
The company expects to complete enrollment in the second group in H1 2025, and data readout is expected later this year, Kobel said.
The company's shares were down past 6% in recent trading.
Price: 3.77, Change: -0.26, Percent Change: -6.45
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。